{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:02:43Z","timestamp":1792735363341,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Drug-drug interaction (DDI), which can occur at the pharmacokinetics and\/or the pharmacodynamics (PD) levels, can increase or decrease the therapeutic or adverse response of a drug itself or a combination of drugs. Cancer patients often receive, along their antineoplastic agents, antibiotics such as \u00df-lactams to treat or prevent infection. Despite the narrow therapeutic indices of antibiotics and antineoplastic agents, data about their potential interaction are insufficient. 5-fluorouracil (5-FU), widely used against colon cancer, is known for its toxicity and large intra- and inter- individual variability. Therefore, knowledge about its interaction with antibiotics is crucial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study, we evaluated at the PD levels, against HCT-116 colon cancer cells, DDI between 5-FU and several \u00df-lactams (ampicillin, benzypenicillin, piperacillin, meropenem, flucloxacillin, ceftazidime (CFT), and cefepime (CFP)), widely used in intensive care units. All drugs were tested at clinically achieved concentrations. MTT assay was used to measure the metabolic activity of the cells. Cell cycle profile and apoptosis induction were monitored, in HCT-116 and DLD-1 cells, using propidium iodide staining and Caspase-3\/7 activity assay. The uptake of CFT and CFP by the cells was measured using LC-MS\/MS method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our data indicate that despite their limited uptake by the cells, CFT and CFP (two cephalosporins) antagonized significantly 5-FU-induced S-phase arrest (DLD-1 cells) and apoptosis induction (HCT-116 cells). Remarkably, while CFP did not affect the proliferation of colon cancer cells, CFT inhibited, at clinically relevant concentrations, the proliferation of DLD-1 cells via apoptosis induction, as evidenced by an increase in caspase 3\/7 activation. Unexpectedly, 5-FU also antagonized CFT\u2019s induced cell death in DLD-1 cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study shows that CFP and CFT have adverse effects on 5-FU\u2019s action while CFT is a potent anticancer agent that inhibits DLD-1 cells by inducing apoptotic cell death. Further studies are needed to decipher the mechanism(s) responsible for CFT\u2019s effects against colon cancer as well as the observed antagonism between CFT, CFP, and 5-FU with the ultimate aim of translating the findings to the clinical settings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09125-4","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T11:17:57Z","timestamp":1643627877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ceftazidime and cefepime antagonize 5-fluorouracil\u2019s effect in colon cancer cells"],"prefix":"10.1186","volume":"22","author":[{"given":"Christina","family":"Pfab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anush","family":"Abgaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Danzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatme","family":"Mourtada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weaam","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2278-8586","authenticated-orcid":false,"given":"Nahed","family":"El-Najjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"9125_CR1","doi-asserted-by":"publisher","unstructured":"Huang S-M, Strong JM, Zhang L, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol. 2008;48:662\u201370. https:\/\/doi.org\/10.1177\/0091270007312153.","DOI":"10.1177\/0091270007312153"},{"key":"9125_CR2","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1016\/j.xphs.2017.04.004","volume":"106","author":"J Yu","year":"2017","unstructured":"Yu J, Zhou Z, Tay-Sontheimer J, et al. Intestinal drug interactions mediated by OATPs: a systematic review of preclinical and clinical findings. J Pharm Sci. 2017;106:2312\u201325. https:\/\/doi.org\/10.1016\/j.xphs.2017.04.004.","journal-title":"J Pharm Sci"},{"key":"9125_CR3","doi-asserted-by":"publisher","first-page":"e12944","DOI":"10.1111\/ecc.12944","volume":"28","author":"G Riu-Viladoms","year":"2019","unstructured":"Riu-Viladoms G, Carcelero San Mart\u00edn E, Mart\u00edn-Conde MT, et al. Drug interactions with oral antineoplastic drugs: the role of the pharmacist. Eur J Cancer Care (Engl). 2019;28:e12944. https:\/\/doi.org\/10.1111\/ecc.12944.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"9125_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1208\/s12248-009-9106-3","volume":"11","author":"L Zhang","year":"2009","unstructured":"Zhang L, Zhang Y, Zhao P, et al. Predicting drug-drug interactions: an FDA perspective. AAPS J. 2009;11:300\u20136. https:\/\/doi.org\/10.1208\/s12248-009-9106-3.","journal-title":"AAPS J"},{"key":"9125_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2796.2001.00892.x","volume":"250","author":"I Buajordet","year":"2001","unstructured":"Buajordet I, Ebbesen J, Erikssen J, et al. Fatal adverse drug events: the paradox of drug treatment. J Intern Med. 2001;250:327\u201341. https:\/\/doi.org\/10.1111\/j.1365-2796.2001.00892.x.","journal-title":"J Intern Med"},{"key":"9125_CR6","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1515\/cclm-2016-0700","volume":"55","author":"N El-Najjar","year":"2017","unstructured":"El-Najjar N, Jantsch J, Gessner A. The use of liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of antibiotics in cancer patients. Clin Chem Lab Med. 2017;55:1246\u201361. https:\/\/doi.org\/10.1515\/cclm-2016-0700.","journal-title":"Clin Chem Lab Med"},{"key":"9125_CR7","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/bjc.2013.48","volume":"108","author":"RWF van Leeuwen","year":"2013","unstructured":"van Leeuwen RWF, Brundel DHS, Neef C, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108:1071\u20138. https:\/\/doi.org\/10.1038\/bjc.2013.48.","journal-title":"Br J Cancer"},{"key":"9125_CR8","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/s0959-8049(02)00151-x","volume":"38","author":"A Felici","year":"2002","unstructured":"Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002;38:1677\u201384. https:\/\/doi.org\/10.1016\/s0959-8049(02)00151-x.","journal-title":"Eur J Cancer"},{"key":"9125_CR9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/cid\/ciy258","volume":"67","author":"R Ram","year":"2018","unstructured":"Ram R, Halavy Y, Amit O, et al. Extended vs bolus infusion of broad-spectrum \u03b2-lactams for febrile neutropenia: an unblinded, randomized trial. Clin Infect Dis. 2018;67:1153\u201360. https:\/\/doi.org\/10.1093\/cid\/ciy258.","journal-title":"Clin Infect Dis"},{"key":"9125_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/1078155216687151","volume":"24","author":"RH Wrenn","year":"2018","unstructured":"Wrenn RH, Cluck D, Kennedy L, et al. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia. J Oncol Pharm Pract. 2018;24:170\u20135. https:\/\/doi.org\/10.1177\/1078155216687151.","journal-title":"J Oncol Pharm Pract"},{"key":"9125_CR11","first-page":"435","volume":"48","author":"W Wang","year":"2019","unstructured":"Wang W, Xiao B, Liu Z, et al. The prevalence of the potential drug-drug interactions involving anticancer drugs in China: a retrospective study. Iran J Public Health. 2019;48:435\u201343.","journal-title":"Iran J Public Health"},{"key":"9125_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pharmthera.2006.03.003","volume":"112","author":"Y Shitara","year":"2006","unstructured":"Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112:71\u2013105. https:\/\/doi.org\/10.1016\/j.pharmthera.2006.03.003.","journal-title":"Pharmacol Ther"},{"key":"9125_CR13","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/jnci\/80.19.1560","volume":"80","author":"JG Park","year":"1988","unstructured":"Park JG, Collins JM, Gazdar AF, et al. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst. 1988;80:1560\u20134. https:\/\/doi.org\/10.1093\/jnci\/80.19.1560.","journal-title":"J Natl Cancer Inst"},{"key":"9125_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clcc.2014.11.002","volume":"14","author":"B Gustavsson","year":"2015","unstructured":"Gustavsson B, Carlsson G, Machover D, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14:1\u201310. https:\/\/doi.org\/10.1016\/j.clcc.2014.11.002.","journal-title":"Clin Colorectal Cancer"},{"issue":"Suppl","key":"9125_CR15","first-page":"215","volume":"14","author":"RE Brummett","year":"1981","unstructured":"Brummett RE. Ototoxicity resulting from the combined administration of potent diuretics and other agents. Scand Audiol Suppl. 1981;14(Suppl):215\u201324.","journal-title":"Scand Audiol Suppl"},{"key":"9125_CR16","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1200\/JCO.2005.03.9909","volume":"24","author":"J Klastersky","year":"2006","unstructured":"Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24:4129\u201334. https:\/\/doi.org\/10.1200\/JCO.2005.03.9909.","journal-title":"J Clin Oncol"},{"key":"9125_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/00043426-200205000-00021","volume":"24","author":"J-H Dalle","year":"2002","unstructured":"Dalle J-H, Auvrignon A, Vassal G, et al. Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol. 2002;24:321\u20132. https:\/\/doi.org\/10.1097\/00043426-200205000-00021.","journal-title":"J Pediatr Hematol Oncol"},{"key":"9125_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.medmal.2012.11.006","volume":"43","author":"A Jarfaut","year":"2013","unstructured":"Jarfaut A, Santucci R, Lev\u00eaque D, et al. Severe methotrexate toxicity due to a concomitant administration of ciprofloxacin. Med Mal Infect. 2013;43:39\u201341. https:\/\/doi.org\/10.1016\/j.medmal.2012.11.006.","journal-title":"Med Mal Infect"},{"key":"9125_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/BF02897260","volume":"26","author":"H Iven","year":"1990","unstructured":"Iven H, Brasch H. Cephalosporins increase the renal clearance of methotrexate and 7-hydroxymethotrexate in rabbits. Cancer Chemother Pharmacol. 1990;26:139\u201343. https:\/\/doi.org\/10.1007\/BF02897260.","journal-title":"Cancer Chemother Pharmacol"},{"key":"9125_CR20","first-page":"291","volume":"9","author":"M Falchi","year":"1989","unstructured":"Falchi M, Scaltrito M, Aresca P, et al. Antibacterial and cytotoxic effect of ceftazidime-mitoxantrone association. Anticancer Res. 1989;9:291\u20132.","journal-title":"Anticancer Res"},{"key":"9125_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12885-015-1560-y","volume":"15","author":"V Yadav","year":"2015","unstructured":"Yadav V, Varshney P, Sultana S, et al. Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation. BMC Cancer. 2015;15:581. https:\/\/doi.org\/10.1186\/s12885-015-1560-y.","journal-title":"BMC Cancer"},{"key":"9125_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.1476-5381.2009.00161.x","volume":"157","author":"LA Bourikas","year":"2009","unstructured":"Bourikas LA, Kolios G, Valatas V, et al. Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br J Pharmacol. 2009;157:362\u201370. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00161.x.","journal-title":"Br J Pharmacol"},{"key":"9125_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/jac\/18.6.703","volume":"18","author":"Y Yamashiro","year":"1986","unstructured":"Yamashiro Y, Fukuoka Y, Yotsuji A, et al. Interactions of antimicrobial agents and antineoplastic agents. J Antimicrob Chemother. 1986;18:703\u20138. https:\/\/doi.org\/10.1093\/jac\/18.6.703.","journal-title":"J Antimicrob Chemother"},{"key":"9125_CR24","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000238445","volume":"32","author":"JH Gieringer","year":"1986","unstructured":"Gieringer JH, Wenz AF, Just HM, et al. Effect of 5-fluorouracil, mitoxantrone, methotrexate, and vincristine on the antibacterial activity of ceftriaxone, ceftazidime, cefotiam, piperacillin, and netilmicin. Chemotherapy. 1986;32:418\u201324. https:\/\/doi.org\/10.1159\/000238445.","journal-title":"Chemotherapy"},{"key":"9125_CR25","doi-asserted-by":"publisher","first-page":"106195","DOI":"10.1016\/j.eplepsyres.2019.106195","volume":"157","author":"K Suemaru","year":"2019","unstructured":"Suemaru K, Yoshikawa M, Aso H, et al. 5-Fluorouracil exacerbates cefepime-induced convulsions in pentylenetetrazol-kindled mice. Epilepsy Res. 2019;157:106195. https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106195.","journal-title":"Epilepsy Res"},{"key":"9125_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.clcc.2016.04.001","volume":"15","author":"M Wilhelm","year":"2016","unstructured":"Wilhelm M, Mueller L, Miller MC, et al. Prospective, multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice. Clin Colorectal Cancer. 2016;15:381\u20138. https:\/\/doi.org\/10.1016\/j.clcc.2016.04.001.","journal-title":"Clin Colorectal Cancer"},{"key":"9125_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.phrs.2004.01.006","volume":"50","author":"F Casale","year":"2004","unstructured":"Casale F, Canaparo R, Serpe L, et al. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res. 2004;50:173\u20139. https:\/\/doi.org\/10.1016\/j.phrs.2004.01.006.","journal-title":"Pharmacol Res"},{"key":"9125_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","volume":"78","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol. 2016;78:447\u201364. https:\/\/doi.org\/10.1007\/s00280-016-3054-2.","journal-title":"Cancer Chemother Pharmacol"},{"key":"9125_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3109\/07357909409024872","volume":"12","author":"CG Leichman","year":"1994","unstructured":"Leichman CG. Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials. Cancer Investig. 1994;12:166\u201375. https:\/\/doi.org\/10.3109\/07357909409024872.","journal-title":"Cancer Investig"},{"key":"9125_CR30","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1128\/AAC.01141-08","volume":"53","author":"AM Nicasio","year":"2009","unstructured":"Nicasio AM, Ariano RE, Zelenitsky SA, et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2009;53:1476\u201381. https:\/\/doi.org\/10.1128\/AAC.01141-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"9125_CR31","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1128\/aac.31.5.698","volume":"31","author":"MD Reed","year":"1987","unstructured":"Reed MD, Stern RC, O'Brien CA, et al. Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis. Antimicrob Agents Chemother. 1987;31:698\u2013702. https:\/\/doi.org\/10.1128\/aac.31.5.698.","journal-title":"Antimicrob Agents Chemother"},{"key":"9125_CR32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/dta.2253","volume":"10","author":"N El-Najjar","year":"2018","unstructured":"El-Najjar N, H\u00f6sl J, Holzmann T, et al. UPLC-MS\/MS method for therapeutic drug monitoring of 10 antibiotics used in intensive care units. Drug Test Anal. 2018;10:584\u201391. https:\/\/doi.org\/10.1002\/dta.2253.","journal-title":"Drug Test Anal"},{"key":"9125_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/sj.bjc.6605780","volume":"103","author":"K Bracht","year":"2010","unstructured":"Bracht K, Nicholls AM, Liu Y, et al. 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. Br J Cancer. 2010;103:340\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6605780.","journal-title":"Br J Cancer"},{"key":"9125_CR34","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/s0022-3476(05)83351-7","volume":"117","author":"G Ferrazzini","year":"1990","unstructured":"Ferrazzini G, Klein J, Sulh H, et al. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr. 1990;117:823\u20136. https:\/\/doi.org\/10.1016\/s0022-3476(05)83351-7.","journal-title":"J Pediatr"},{"key":"9125_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0005-2736(90)90309-C","volume":"1027","author":"AH Dantzig","year":"1990","unstructured":"Dantzig AH, Bergin L. Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2. Biochim Biophys Acta. 1990;1027:211\u20137. https:\/\/doi.org\/10.1016\/0005-2736(90)90309-C.","journal-title":"Biochim Biophys Acta"},{"key":"9125_CR36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00003088-200039050-00003","volume":"39","author":"I Lutsar","year":"2000","unstructured":"Lutsar I, Friedland IR. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet. 2000;39:335\u201343. https:\/\/doi.org\/10.2165\/00003088-200039050-00003.","journal-title":"Clin Pharmacokinet"},{"key":"9125_CR37","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/archderm.119.6.449","volume":"119","author":"DW Nierenberg","year":"1983","unstructured":"Nierenberg DW, Mamelok RD. Toxic reaction to methotrexate in a patient receiving penicillin and furosemide: a possible interaction. Arch Dermatol. 1983;119:449\u201350. https:\/\/doi.org\/10.1001\/archderm.119.6.449.","journal-title":"Arch Dermatol"},{"key":"9125_CR38","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui C-H, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21:1471\u201382. https:\/\/doi.org\/10.1634\/theoncologist.2015-0164.","journal-title":"Oncologist"},{"key":"9125_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/157488409789375348","volume":"4","author":"D Lev\u00eaque","year":"2009","unstructured":"Lev\u00eaque D, Jehl F. Molecular determinants of fluoroquinolone antibacterial agents pharmacokinetics. Curr Clin Pharmacol. 2009;4:191\u20137. https:\/\/doi.org\/10.2174\/157488409789375348.","journal-title":"Curr Clin Pharmacol"},{"key":"9125_CR40","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/00007691-200208000-00018","volume":"24","author":"K Titier","year":"2002","unstructured":"Titier K, Lagrange F, P\u00e9hourcq F, et al. Pharmacokinetic interaction between high-dose methotrexate and oxacillin. Ther Drug Monit. 2002;24:570\u20132. https:\/\/doi.org\/10.1097\/00007691-200208000-00018.","journal-title":"Ther Drug Monit"},{"key":"9125_CR41","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/ijc.11528","volume":"108","author":"K Shiozawa","year":"2004","unstructured":"Shiozawa K, Oka M, Soda H, et al. Reversal of breast cancer resistance protein (BCRP\/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer. 2004;108:146\u201351. https:\/\/doi.org\/10.1002\/ijc.11528.","journal-title":"Int J Cancer"},{"key":"9125_CR42","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.2741\/1420","volume":"9","author":"D Kuhn","year":"2004","unstructured":"Kuhn D, Coates C, Daniel K, et al. Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs. Front Biosci. 2004;9:2605\u201317. https:\/\/doi.org\/10.2741\/1420.","journal-title":"Front Biosci"},{"key":"9125_CR43","doi-asserted-by":"publisher","unstructured":"Zhang X, Jia Y. Recent advances in \u03b2-lactam derivatives as potential anticancer agents. Curr Top Med Chem. 2020. https:\/\/doi.org\/10.2174\/1568026620666200309161444.","DOI":"10.2174\/1568026620666200309161444"},{"key":"9125_CR44","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1128\/aac.35.11.2312","volume":"35","author":"MJ Pucci","year":"1991","unstructured":"Pucci MJ, Boice-Sowek J, Kessler RE, et al. Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991;35:2312\u20137. https:\/\/doi.org\/10.1128\/aac.35.11.2312.","journal-title":"Antimicrob Agents Chemother"},{"key":"9125_CR45","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3892\/ijmm.2015.2297","volume":"36","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Bi C, Fan Y, et al. Cefepime, a fourth-generation cephalosporin, in complex with manganese, inhibits proteasome activity and induces the apoptosis of human breast cancer cells. Int J Mol Med. 2015;36:1143\u201350. https:\/\/doi.org\/10.3892\/ijmm.2015.2297.","journal-title":"Int J Mol Med"},{"key":"9125_CR46","doi-asserted-by":"publisher","first-page":"33919","DOI":"10.18632\/oncotarget.8984","volume":"7","author":"E Labay","year":"2016","unstructured":"Labay E, Mauceri HJ, Efimova EV, et al. Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers. Oncotarget. 2016;7:33919\u201333. https:\/\/doi.org\/10.18632\/oncotarget.8984.","journal-title":"Oncotarget"},{"key":"9125_CR47","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/archderm.1983.01650300003001","volume":"119","author":"RD Mamelok","year":"1983","unstructured":"Mamelok RD. Toxic reaction to methotrexate in a patient receiving penicillin and furosemide: a possible interaction. Arch Dermatol. 1983;119:449. https:\/\/doi.org\/10.1001\/archderm.1983.01650300003001.","journal-title":"Arch Dermatol"},{"key":"9125_CR48","doi-asserted-by":"publisher","first-page":"13059","DOI":"10.18632\/oncotarget.14371","volume":"8","author":"J Sommer","year":"2017","unstructured":"Sommer J, Mahli A, Freese K, et al. Analysis of molecular mechanisms of 5-fluorouracil-induced steatosis and inflammation in vitro and in mice. Oncotarget. 2017;8:13059\u201372. https:\/\/doi.org\/10.18632\/oncotarget.14371.","journal-title":"Oncotarget"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09125-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09125-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09125-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T11:22:45Z","timestamp":1643628165000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09125-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9125"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09125-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"16 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}